Across bioprocessing applications, we can help you adapt to changing market conditions with innovative technologies and solutions. Whether that means quickly developing a process for a new nucleic acid therapeutic, producing a vaccine, or making existing processes easier, faster and better, we are here for you.
To deliver on the promise of mRNA technology, the industry must develop platform processes – from making the DNA template and mRNA molecules through purifying, encapsulating, filling, and testing. Solutions must be both scalable and flexible.
Mechanistic modeling complements other process development approaches. Compared with HTPD and DoE, it allows better understanding of both the entire process and the parameters that can influence your process. And it requires fewer experiments. As a result, you can get more from your process development – more speed and more reliable results. But there’s a learning curve.
Select the parameters that are used in your upstream bioreactor or downstream capture step then gain insights on how your process can be intensified.
The COVID-19 pandemic brought mRNA vaccines to the spotlight with the rapid release of highly efficacious vaccines by Pfizer/BioNTech and Moderna.
Whether you’re waiting for a production slot with a qualified CDMO or ready to build, a flexible strategy can help you scale quickly, to produce the right quantity at the right time..
A case study on improving single-use training through vendor and end-user collaboration.
On May 1 the biotechnology, laboratory and medical businesses of Pall Corporation became part of Cytiva. You'll now find the same great Pall products and content hosted here.